SNSE Sensei Biotherapeutics
- 1.650
- +0.390+30.95%
- 1.690
- +0.040+2.42%
Sensei Biotherapeutics News
JAGX, SNSE and BON Among Mid-day Movers
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
Sensei Biotherapeutics to Present Topline Clinical Data From the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeut
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
Sensei Biotherapeutics Extends Relationship With Former CFO
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today
Express News | Sensei Biotherapeutics Shares Are Trading Higher After the Company Announced the Publication of a Peer-reviewed Research Paper in Nature Communications the Described the Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA Within
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA Within the Tumor Microenvironment
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced the publication of a peer-reviewed research paper in Nature Communications.
Sensei Biotherapeutics CFO Erin Colgan Resigns Amicably
Express News | Sensei Biotherapeutics CFO To Resign All Positions With Co Effective April 10
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Sensei Biotherapeutics (SNSE)
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
Sensei Biotherapeutics (SNSE) Gets a Buy From Oppenheimer
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE), Abbott Labs (ABT) and Personalis (PSNL)
Buy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical Trials
Sensei Biotherapeutics Reports FY Results
Sensei Biotherapeutics FY EPS $(1.22) Up From $(1.58) YoY; 2023 Year End Cash, Cash Equivalents And Marketable Securities Of $65.8M Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(1.22) per share. This is a 22.78 percent increase over losses of $(1.58) per share from the same period last year.
Sensei Biotherapeutics: Runway To Fund Operation Into 4Q 2025 >SNSE
Sensei Biotherapeutics: Runway To Fund Operation Into 4Q 2025 >SNSE
Sensei Biotherapeutics Streamlines Board, Appoints Interim Chair
Analysis
Price Target
No Data
